This investigation was conducted to determine the effect of estrogen replacement therapy (ERT) on vitamin B-6 status of postmenopausal women. Nineteen postmenopausal women served as subjects. Nine (54.7 + 4.7 years) were taking ERT (experimental group); ten (56.8 + 2.3 years) were not (control group). For three consecutive days, subjects recorded their dietary intake and collected their 24-hour urine specimens. On the fourth day, a fasting blood sample was drawn from the subjects. The dietary intake of vitamin B-6, as well as the concentration of total vitamin B-6 in plasma (PB6; and urine (UB6) were measured. PB6 and UB6 were determined by a microbiological method with Saccharomyces uvarum as the assay organism. The mean age, height, hematocrit and hemoglobin values were similar for the two groups. The experimental group was significantly heavier than the control group (p<0.05). The experimental group had a lower mean PB6 than the control group: 47.7 ± 19.7 nmol/L vs. 56.2 + 20.6 nmol/L. These means were not significantly different (p=0.05). PB6 was positively correlated with dietary vitamin B-6 intake (p=0.0001) and vitamin B-6 to protein ratio (p=0.0021). When the means were adjusted for dietary vitamin B-6 and the vitamin B-6 to protein ratio, the mean PB6 of the experimental group (42.7 nmol/L) was significantly lower than that of the control group (60.6 nmol/L) (p<0.05). PB6 was not positively correlated with either age (r=0.20) or the vitamin B-6 dietary history score (r=0.15). UB6 was similar for the two groups. UB6 correlated positively with daily dietary intake of vitamin B-6 (r=0.51, p<0.05) and the ratio of vitamin B-6 to protein (r=0.47, p<0.05), UB6 was not significantly correlated to urine volume (r=0.05). The mean daily intakes of vitamin B-6 and protein were similar for the two groups. One of the 19 subjects had a vitamin B-6 intake that was less than 67 percent of the RDA. Most subjects' (89%) intake of vitamin B-6 was adequate when the ratio of 0.016 mg of vitamin B-6 per g of protein was used as the standard. / Graduation date: 1990

Call number: LD2668 .T4 1986 M37 / Master of Science / Human Nutrition

Malaria ist eine schwerwiegende Krankheit, die jährlich über eine Million Menschen tötet. Die zunehmende Resistenzbildung gegenüber den verwendeten Medikamenten macht die Entwicklung neuer Antimalariamittel dringend notwendig. Daher sind die Vitamin B6 Synthese und der Shikimatweg von besonderem Interesse, da diese beiden Synthesewege nur im Parasiten und nicht im Menschen vorkommen. Unter der Voraussetzung, dass diese essentiell für den Parasiten sind, böten sie ideale Ansatzpunkte zur Entwicklung neuer Antimalariamittel. Voraus gegangene Studien haben gezeigt, dass Plasmodium falciparum in der Lage ist, PLP de novo mittels eines bifunktionalen Enzymkomplex, bestehend aus den Proteinen Pdx1 und Pdx2, zu synthetisieren. Pdx1 stellt dabei die eigentliche Synthase dar, während Pdx2 als Glutaminase-Partner das benötigte Ammoniumion für den heterocyclen Ring bereitstellt. Zusätzlich dazu verfügt der Parasit auch über einen salvage pathway um PLP zu „recyclen“, in dem der Pyridoxalkinase PdxK eine Schlüsselfunktion zufällt. Knockout Studien der pdx1 im Mausmalariasystem P. berghei haben gezeigt, dass PbPdx1 für eine optimale Entwicklung der Blutstadien benötigt wird, nicht jedoch für deren Überleben. Im Rahmen dieser Arbeit habe ich die Effekte eines pbpdxK(-) Knockouts in demselben System untersucht. Es konnte eine monoklonale Knockoutlinie generiert werden, was zeigte, dass PbPdxK nicht essentiell für das Überleben des Parasiten in den Blutstadien ist. Die Entwicklung während des Blutstadiums war von dem pbpdxK(-) Knockout nicht betroffen. Allerdings zeigte sich im Moskitostadium eine drastische Reduktion der Sporozoitenzahl sowohl in den Mitteldärmen als auch in den Speicheldrüsen. Dieses Ergebnis legt nahe, dass PbPdxK essentiell für das Überleben der Sporozoiten ist. Daneben wurde versucht, die Gene pfpdx1, pfpdx2 sowie pfpdxK in P. falciparum 3D7 durch Verwendung der single cross over Strategie auszuschalten. Es konnte jedoch für keines der genannten Konstrukte eine Integration in die jeweiligen Genloci anhand von PCR-Analysen nachgewiesen werden. Ebenso scheiterte der Versuch, durch Rekombination eines komplementären Genabschnitts die Funktion des Gens zu rekonstituieren. Daher bleibt es unklar, ob pfpdx1, pfpdx2 und pfpdxK durch Knockout Strategien auszuschalten sind oder nur für Genmanipulationen nicht zugänglich sind. Die Kultivierung von P. falciparum 3D7 Parasiten in Vitamin B6 depletiertem Medium hatte keinen Effekt auf deren Wachstum. Eine anschließende Analyse der Proteinextrakte zeigte eine erhöhte Expression der PfPdxK, während sich das Expressionslevel der PfPdx1 nicht veränderte. Es scheint, dass der Parasit in der Lage ist Vitamin B6 Mangel durch vermehrte Nutzung des salvage pathways vollständig zu kompensieren. Frühere Arbeiten zeigten, dass der C-Terminus der Pdx1 in die Aktivität des PLP Synthasekomplexes involviert ist. Aus diesem Grund wurden verschiedene C-terminale Deletionsmutanten der PfPdx1 konstruiert und dabei bis zu 30 Aminosäuren entfernt. Diese Analysen ergaben, dass der C-Terminus vier verschiedene Funktionen besitzt: das Assembly der Pdx1 Untereinheiten zum Dodekamer, die Bindung des Pentosesubstrats Ribose 5-Phosphat, die Bildung des Intermediats I320 und schließlich die PLP Synthese. Diese unterschiedlichen Funktionen wurden durch verschiedene Deletionsvarianten identifiziert. Darüber hinaus waren alle Deletionsvarianten in der Lage, die Glutaminase Pdx2 zu aktivieren, was zeigt, dass das Dodekamer nicht Vorraussetzung für die Glutaminaseaktivität ist. Aufgrund der geringen PLP Syntheseaktivität in vitro wurde vermutet, dass der PfPdx1/PfPdx2 Komplex durch einen zusätzlichen Faktor aktiviert wird. Daher wurde versucht, mittels Yeast 2-Hybrid, basierend auf einer PCR-amplifizierten P. falciparum 3D7 cDNA-Bibliothek als bait und PfPdx1 als prey, einen Interaktionspartner zu identifizieren. Mehrere Klone wurden gewonnen, die alle einen Bereich des Mal13P1.540, einem putativen Hsp70 Proteins, enthielten. Jedoch scheiterten alle Versuche, die Protein-Protein-Interaktion mit rekombinant exprimierten Protein zu bestätigen. Ebenso war es nicht möglich, das vollständige Mal13P1.540 rekombinant zu exprimieren sowie dessen Lokalisation in vivo zu bestimmen. Daher bleibt die Interaktion von PfPdx1 und Mal13P1.540 ungeklärt. Neben der Vitamin B6 Biosynthese konnten auch einige Gene des Shikimatweges in Plasmodium identifiziert werden. In P. berghei konnten der C-terminale Teil der 3-Dehydroquinatsynthase (2) sowie die Shikimatkinase (5) und die 5-Enoylpyruvylshikimat 3-Phosphatsynthase (6) in einem open reading frame (ORF) identifiziert werden, der dieselbe genetische Organisation aufweisen wie der Arom-Komplex der Hefen. Mit Hilfe eines Komplementationsassay wurde die Funktionalität dieses ORFs überprüft. Dazu wurden S. cerevisiae BY4741Δaro1, ein Hefestamm ohne funktionalen Arom-Komplex, mit dem Pb2_6_5_ABC Fragment transformiert. Die so transformierten Hefen waren nicht in der Lage, auf Mangelplatten ohne aromatische Aminosäuren zu wachsen, was zeigte, dass das Pb2_6_5_ABC Konstrukt den BY4741Δaro1 Phänotyp nicht komplementieren konnte. Der Versuch, mit Hilfe des Baculovirussytems rekombiant exprimiertes Protein zu erhalten, verlief erfolglos. Ebenso war es nicht möglich, Teile des Proteins für Immunisierungen zu exprimieren. Daher bleibt die Funktionalität des Pb2_6_5_ABC Konstruktes ungeklärt. / Malaria is a serious burden of mankind causing over one million deaths a year. In view of the raising number of resistances to common drugs there is an urgent need for the development of new antimalarial drugs. In this respect, the vitamin B6 biosynthesis and the shikimate pathway are of particular interest, since these synthesis pathways are only present in the malarial parasites and not in their human host. Given their essentiality for the parasite, they would represent ideal targets for antimalarial drug development. Previous studies revealed that Plasmodium falciparum is able to produce PLP de novo through a bifunctional enzyme complex composed of the proteins Pdx1 and Pdx2, of which Pdx1 is the actual synthase and Pdx2 the glutaminase partner providing the nitrogen for the ring system. In addition, the parasites possess a salvage pathway for PLP, of which pyridoxal kinase, PdxK, is a key player. Knockout studies of the pdx1 in the rodent malaria system P. berghei showed, that pbpdx1 is required for the optimal development of parasite blood stages but is not essential for parasite survival. Here, I investigated the effect of a pbpdxK(-) knockout in the same system. A monoclonal knockout strain was obtained, indicating that PbPdxK is not essential for the survival of the parasite. Blood stages were not affected by the knockout. However, in the mosquito stages pbpdxK(-) showed a tremendous reduction of sporozoites numbers in the midgut and in the salivary glands, indicating that PbPdxK is essential for the survival of sporozoites. It was then also tried to knockout pfpdx1, pfpdx2 and pfpdxK in the P. falciparum 3D7 strain by using the single cross over strategy. However, no integration of the constructs in the corresponding gene locus could be detected by a PCR approach. Also an approach to complement the loss of endogenous gene function by generating a functional gene copy upon recombination failed. Thus, it remains unclear if pfpdx1, pfpdx2 and pfpdxK can be knocked out or are inaccessible for gene targeting in P. falciparum. Cultivation of P. falciparum 3D7 parasites in medium deficient of vitamin B6 showed no effect on the growth rate of the parasites. Analysis of protein extracts of these parasites revealed an upregulation of PfPdxK expression, whereas the level of PfPdx1 remained stable. Thus it seems that the parasite is fully able to compensate vitamin B6 malnutrition by the increased usage of the salvage pathway. Previous studies on the activity of the PLP synthase complex indicated that the C-terminal end of Pdx1 is involved in PLP formation. Therefore several C-terminal deletion mutants of PfPdx1 were constructed, removing up to 30 amino acids. These analyses revealed that the C-terminus has four distinct functionalities: assembly of the Pdx1 monomers, binding of the pentose substrate (ribose 5-phosphate), formation of the reaction intermediate I320, and finally PLP synthesis. Deletions of distinct C-terminal regions distinguish between these individual functions. All variants were able to activate the glutaminase PfPdx2, indicating that the dodecameric structure is not a prerequisite for Pdx2 activation. Due to the low PLP synthase activity in vitro it was assumed that the PfPdx1/PfPdx2 complex maybe activated by an additional protein. Hence a yeast 2-hybrid assay was performed, using PfPdx1 as prey and a PCR-amplified cDNA-library of P. falciparum 3D7 as bait. Several clones were detected on high stringency plates, containing all a region of Mal13P1.540, a putative Hsp70 protein. Trials to confirm protein-protein interaction with recombinantly produced proteins failed as well as protein expression of full length Mal13P1.540. It was also not possible to determine the localisation of Mal13P1.540 in vivo. Thus, an interaction of PfPdx1 with Mal13P1.540 could so far not be verified. Besides the vitamin B6 biosynthesis, some genes of the shikimate pathway were identified in Plasmodium. In P. berghei, the C-terminal part of the dehydroquinatesynthase (2) as well as the shikimate kinase (5) and 5-enoylpyruvylshikimate 3-phosphatesynthase (6) were found in a single open reading frame having the same organisation as the arom-complex of yeast. To proof the functionality of these genes a complementation assay with S. cerevisiae BY4741Δaro1 with the Pb2_6_5_ABC construct, comprising the above mentioned genes, was performed. However, transformded yeast strains were not able to grow on minimal media without aromatic amino acids, indicating that they were not able to produce chorismate. Recombinant expression of this constructs in the baculovirussystem did not yield any detectable protein. Expression of parts of this protein for immunisation was also not successful. Hence, the functionality of this protein remains to be established.

Graduation date: 1992

Graduation date: 1994

El piridoxal 5'-fosfato es la forma biocatalíticamente activa de la vitamina B6, siendo uno de los cofactores más versátiles de la naturaleza, el cuál tiene un papel central en el metabolismo de aminoácidos. Mientras que la mayoria de microorganismos y plantas pueden sintetizar la vitamina B6 de novo, los mamíferos se ven obligados a obtener uno de sus vitámeros a través de la dieta. La maquinaria biosintética de Escherichia coli es, de lejos, la mejor caracterizada y consiste en cuatro proteínas pdx. PdxJ, también conocida como piridoxina 5'-fosfato sintasa, es la enzima clave en esta via. Cataliza el último paso, la complicada reacción de cierre del anillo entre 1-deoxi-D-xilulosa-5-fosfato y aminoacetona-3-fosfato para formar piridoxina 5'-fosfato. La comparación de secuencias de PdxJ entre espécies revela que existe un alto grado de conservación indicando así la enorme importancia fisiológica de esta enzima.Con el uso de un derivado de mercurio fue posible el resolver la estructura cristalina de la enzima de E. coli por el método del "single isomorphous replacement with anomalous scattering" y el refinar la estructura a 2.0 Å de resolución. El monómero corresponde al plegamiento TIM o barril (_/_)8, con la incorporación de tres hélices extra que median los contactos entre intersubunidades en el octámero. El octámero representa el estado fisiológicamente relevante, que fué observado tanto en el cristal como en solución, y que esta organizado como un tetrámero de dímeros activos. La caracterización de la estructura cristalográfica de la enzima con sustratos, análogos de sustrato y productos unidos permitió la identificación del centro activo y la propuesta de un mecanismo detallado. Los rasgos catalíticos más remarcables son: (1) el cierre del centro activo una vez se han unido los sustratos, de manera que el bolsillo de unión queda aislado del solvente y los intermediarios de la reacción quedan así estabilizados; (2) la existencia de dos sitios de unión de fosfato bien definidos; (3) y un canal de agua que penetra el núcleo del barril _ y permite liberar las moléculas de agua formadas durante la reacción.La cantidad de información presentada debería permitir el diseño de inhibidores de la piridoxina 5'-fosfato sintasa basados en su estructura. Es interesante el destacar que entre las bacterias que contienen el gen pdxJ se encuentran unos cuantos patógenos bien conocidos. La resistencia de bacterias contra antibióticos está aumentando cada vez más, hecho que se está convirtiendo en un auténtico problema. Por este motivo, es necesario el desarrollar medicamentos antibacterianos con un alto grado de especificidad y la piridoxina 5'-fosfato sintasa parece ser una diana muy prometedora. / Pyridoxal 5'-phosphate is the biocatalytically active form of vitamin B6, being one of nature's most versatile cofactors that plays a central role in the metabolism of amino acids. Whereas microorganisms and plants can synthetise vitamin B6 de novo, mammals have to obtain one of the B6 vitamers with their diet. The Escherichia coli biosynthetic machinery is the, by far, best characterised and it consists in four pdx proteins. PdxJ, also referred to as pyridoxine 5'-phosphate synthase, is the key enzyme in this pathway. It catalyses the last step, the complicated ring-closure reaction between 1-deoxy-D-xylulose-5-phosphate and aminoacetone-3-phosphate yielding pyridoxine 5'-phosphate. Sequence comparison of PdxJ from different species revealed a remarkable high degree of conservation indicating the paramount physiological importance of this enzyme.With the use of one mercury heavy-atom derivative, it was possible to solve the crystal structure of the E. coli enzyme by the single isomorphous replacement method with anomalous scattering and to refine the structure at 2.0 Å resolution. The monomer folds as a TIM or (_/_)8 barrel, with the incorporation of three extra helices that mediate intersubunits contacts within the octamer. The octamer represents the physiological relevant state that was observed in the crystal and in solution, and that is organised as a tetramer of active dimers. Characterisation of the enzyme crystal structure with bound substrates, substrate analogues, and products allowed the identification of the active site and the proposal of a detailed reaction mechanism. The most important catalytic features are: (1) active site closure upon substrate binding, in order to isolate the specificity pocket from the solvent und thus stabilise the reaction intermediates; (2) the existence of two well-defined phosphate binding sites; (3) and a water channel that penetrates the _ barrel core and allows the release of waters in the closed state.The amount of information here presented should permit the structure-based design of pyridoxine 5'-phosphate synthase inhibitors. Interestingly, among bacteria that contain the pdxJ gene there are several well-known pathogens. More and more, the bacterial resistance against antibiotics is increasing and therefore becoming a real problem. Thus, it is necessary the development of highly specific antibacterial drugs and pyridoxine 5'-phosphate synthase seems to be a promising novel target.

Vitamin B-6 is a vitamin often promoted by the popular press as a cure all. It's role is also being studied in regard to pre-menstrual syndrome, myocardial infarction and alterations in lipid and fatty acid metabolism. This study was designed to investigate whether there was a difference between vitamin B-6 blood levels, during a baseline study, a period of vitamin B-6 depletion and vitamin B-6 supplemention in ten men ages 21-37. The effect of each diet on total cholesterol was also investigated.The experimentally accessible population for this study Laboratory as part of a larger study conducted by Dr. Stephen Coburn of the Fort Wayne State Developmental Center.Analysis of the data indicated:1) A significant difference between red blood cell pyridoxal phosphate and blood plasma levels of vitamin B-6 during the baseline, depletion and supplementation phases in ten men 21-37.2) Total serum cholesterol levels fell significantly through all phases of the study. High density lipoproteins fell significantly during the depletion phase but did not rise significantly during the supplementation phase. Low density lipoproteins showed no significant difference during the three phases of the study. When dietary records were evaluated mean dietary intake during the baseline and supplementation phases of the diet met the Recommended Dietary Allowance (RDA) for vitamin B-6. Mean protein intake also met the RDA with 102.1 grams during the baseline phase and 106.1 grams during the supplementation phase. These intakes are consistent with those found in previous studies conducted by the USDA. Mean intake of fat was lower than the 30 percent of calories recommended by the American Heart Association but wide variation existed among subjects.No physical symptoms of vitamin B-6 deficiency manifested themselves during the study. Subjects reported no other problems associated with low vitamin B-6 intakes.The data indicated that vitamin B-6 intake effects the amount of red blood cell plasma pyridoxal phosphate and plasma vitamin B-6. No clear effect can be found between vitamin B-6 intake and serum cholesterol levels. "Normal" diets also appeared to provide adequate vitamin B-6 to meet both RDA's and somatic needs. Wide variation seems to exist, however, among individuals. / Department of Home Economics

Graduation date: 1999

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.

Thesis (Ph. D.)--Oregon State University, 2008. / Printout. Includes bibliographical references. Also available on the World Wide Web.